Pablo Hendler

Pablo Hendler is a Partner in our firm’s Litigation, Intellectual Property, Patent, and Technology and IP Transactions Practices. His practice focuses on complex litigation in the life sciences field, e.g., pharmaceutical, biotechnology, and medical device litigation. Mr. Hendler has counseled clients for more than 25 years on intellectual property matters. He has extensive experience counseling clients to successfully cross the intersection of FDA and patent law.

Mr. Hendler's experience as a researcher, inventor (U.S. Patent Nos. 5,348,928 and 5,266,188), and litigator allow him to successfully represent clients in numerous patent cases involving: ANDAs (Abbreviated New Drug Applications) concerning inhalation medication for the treatment of asthma, improved oxycodone formulations, extended release and abuse-deterrent opioid analgesics, antifungal agents, and a niacin cholesterol-lowering drug; genetically modified mice; plasmid vectors; nutraceuticals; and autonomous medical imaging, infusion pumps, spinal fusion implants, corn herbicides, purge and trap concentrators for gas chromatography, and machine vision and bar code technologies.

Mr. Hendler’s clients have consistently praised him as an "excellent lawyer" and a “sharpshooting” litigator, particularly for his "sterling" work in ANDA litigations. They are comforted by his "seen-and-done-it-all experience." Consistently recognized as a New York Super Lawyer, Mr. Hendler is a member of various bar and industry associations. He also has written and spoken on a broad range of patent-related topics.

Representative Experience

• Purdue Pharma et al. v. Amneal and Kashiv: Successfully represented Purdue Pharma in Hatch-Waxman patent litigation concerning Amneal/Kashiv’s Abbreviated New Drug Application (ANDA) seeking FDA approval of a generic version of OxyContin®.
• Regeneron Pharmaceuticals v. Ablexis: Successfully defended a biotechnology client against a “mouse” patent, achieving a comprehensive settlement allowing the full implementation of its business strategy.
• Lemelson Foundation v. Symbol Tech. et al.: Executed defense against the Lemelson bar code and machine vision patents, winning across the board, creating new law and protection, that saved industries significant expenses in litigation and licensing fees.
• AstraZeneca v. Apotex: Successfully represented AstraZeneca in obtaining a preliminary injunction against Apotex’s generic version of Pulmicort Respules®.